New Driver Mutations Detected in NSCLC.
Researchers have identified additional driver mutations in non-small cell lung cancer that may guide the development of new targeted drugs and immunotherapy. The findings also highlight key differences between two major NSCLC subtypes that could inform future therapeutic strategies.
D000230:Adenocarcinoma / Q000235:genetics*; D000077192:Adenocarcinoma of Lung; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D053263:Gene Regulatory Networks; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D058990:Molecular Targeted Therapy; D009154:Mutation; D051567:Proto-Oncogene Proteins c-vav / Q000235:genetics; D020837:SOS1 Protein / Q000235:genetics; D017422:Sequence Analysis, DNA; D020729:p120 GTPase Activating Protein / Q000235:genetics
D051567:Proto-Oncogene Proteins c-vav; C557248:RASA1 protein, human; D020837:SOS1 Protein; C496618:VAV1 protein, human; D020729:p120 GTPase Activating Protein